Last reviewed · How we verify

NCT05760560

Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex

Status unknown Last updated 14 April 2023
What this trial tests

trial testing Sugammadex in Postoperative Residual Curarization in 52 participants. Status unknown.

Timeline
15 March 2023
Primary endpoint
31 August 2023
31 August 2024

Quick facts

Lead sponsorSeoul National University Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment52
Start date15 March 2023
Primary completion31 August 2023
Estimated completion31 August 2024
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

19 and older, any sex, with Postoperative Residual Curarization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective observational study. A total 52 patients will be included in this study. We will observe the incidence of postoperative residual neuromuscular blockade in patients receiving sugammadex.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Is quantitative neuromuscular monitoring mandatory after administration of the recommended dose of sugammadex? A prospective observational study.
    Koo CH, Lee S, Yim S, Bae YK, et al · · 2024 · cited 1× · PMID 39419348 · DOI 10.1016/j.accpm.2024.101445

Verify or expand the search:

Other trials of Sugammadex

Trials testing the same drug.

Other recruiting trials for Postoperative Residual Curarization

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05760560.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing